Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

Autor: Spriano F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Sartori G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Sgrignani J; Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona., Barnabei L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Arribas AJ; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne., Guala M; Chimete, Tortona., Del Amor AMC; Department of Biomedical and Clinical Sciences, Cell Biology, Medical Faculty, Linköping University, Linköping., Tomasso MR; Drexel University, College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, PA., Tarantelli C; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Cascione L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne., Golino G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Department of Pharmacy, University of Napoli Federico II, Napoli., Riveiro ME; Early Drug Development Group, Boulogne-Billancourt., Bortolozzi R; Department of Woman's and Child's Health, University of Padova, Italy; Istituto di Ricerca Pediatrica IRP, Fondazione Città della Speranza, Padova., Lupia A; Department of Pharmacy, University of Napoli Federico II, Napoli, Italy; Net4science Srl, Magna Graecia University of Catanzaro, Catanzaro., Paduano F; University 'Magna Græcia' of Catanzaro, Catanzaro, Italy; Tecnologica Research Institute and Marrelli Health, Biomedical Section, Stem Cells and Medical Genetics Units, Crotone., Huguet S; Institut Curie, Paris., Rezai K; Institut Curie, Paris., Rinaldi A; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Margheriti F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Ventura P; Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona., Guarda G; Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona., Costa G; University 'Magna Græcia' of Catanzaro, Catanzaro., Rocca R; University 'Magna Græcia' of Catanzaro, Catanzaro., Furlan A; Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona., Verdonk LM; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden., Innocenti P; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden., Martin NI; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Leiden., Viola G; Department of Woman's and Child's Health, University of Padova, Italy; Istituto di Ricerca Pediatrica IRP, Fondazione Città della Speranza, Padova., Driessen C; Kantosspital St Gallen, St Gallen., Zucca E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona., Stathis A; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona., Gahtory D; BIMINI Biotech B.V., Leiden., Van den Nieuwboer M; BIMINI Biotech B.V., Leiden., Bornhauser B; Children's Hospital Zurich, Zurich., Alcaro S; University 'Magna Græcia' of Catanzaro, Catanzaro., Trapasso F; University 'Magna Græcia' of Catanzaro, Catanzaro., Cristobal S; Department of Biomedical and Clinical Sciences, Cell Biology, Medical Faculty, Linköping University, Linköping, Sweden; Ikerbasque, Basque Foundation for Sciences, Department of Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country., Padrick SB; Drexel University, College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, PA., Pazzi N; Chimete, Tortona., Cavalli F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona., Cavalli A; Institute of Research in Biomedicine, Faculty of Biomedical Sciences, USI, Bellinzona., Gaudio E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona. eugaudio1976@gmail.com., Bertoni F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona. francesco.bertoni@ior.usi.ch.

Publikováno v: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3602-3614. Date of Electronic Publication: 2024 Nov 01.

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors.

Autor: Sigaud R; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Dussault N; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Berenguer-Daizé C; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Vellutini C; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Benyahia Z; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Cayol M; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Parat F; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France., Mabrouk K; Aix Marseille University, CNRS, Institut de Chimie Radicalaire (ICR), Unité Mixte de Recherche (UMR) 7273 Chimie Radicalaire Organique et Polymères de Spécialité (CROPS), Marseille, France., Vázquez R; Preclinical Department, Early Drug Development Group (E2DG), Boulogne-Billancourt, France.; Center for Genomic Science of Istituto Italiano di Tecnologia, Center for Genomic Science, European School of Molecular Medicine (IIT@SEMM), Fondazione Istituto Italiano di Tecnologia (IIT), Milan, Italy., Riveiro ME; Preclinical Department, Early Drug Development Group (E2DG), Boulogne-Billancourt, France., Metellus P; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France.; Centre Hospitalier Clairval, Département de Neurochirurgie, Marseille, France., Ouafik L; Aix Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut de Neurophysiopathologie( INP), Inst Neurophysiopathol, Marseille, France.; Assistance Publique Hôpitaux de Marseille (APHM), Centre Hospitalo Universitaire (CHU) Nord, Service d'OncoBiologie, Marseille, France.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Oct 08; Vol. 11, pp. 753244. Date of Electronic Publication: 2021 Oct 08 (Print Publication: 2021).

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.

Autor: De Dosso S; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. sara.dedosso@eoc.ch., Nucifora M, Sahnane N, Epistolio S, Riveiro ME, Bertolini V, Bucci E, Boldorini R, Freguia S, Frattini M, Saletti P

Publikováno v: European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2020 Mar; Vol. 24 (6), pp. 2994-3003.

Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Autor: Civenni G; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Bosotti R; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Timpanaro A; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Vàzquez R; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Merulla J; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Pandit S; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Rossi S; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Albino D; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Allegrini S; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Mitra A; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Mapelli SN; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland; Institute of Computational Science, Università della Svizzera Italiana (USI), Lugano 6900, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland., Vierling L; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Giurdanella M; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Marchetti M; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Paganoni A; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Rinaldi A; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Losa M; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Mira-Catò E; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., D'Antuono R; Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Morone D; Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Rezai K; Institute Curie-Hospital René Huguenin, Saint Cloud 92210, France., D'Ambrosio G; IRCCS Multimedica, Milan 20122, Italy., Ouafik L; Aix-Marseille Université, Inserm, Marseille 13007, France., Mackenzie S; Oncology Therapeutic Development (OTD), Clichy 92110, France., Riveiro ME; Oncology Therapeutic Development (OTD), Clichy 92110, France., Cvitkovic E; Oncology Therapeutic Development (OTD), Clichy 92110, France; Oncoethix GmbH, Merck Sharp and Dohme Corp., Lucerne 6006, Switzerland., Carbone GM; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland., Catapano CV; Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona 6500, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005, Switzerland. Electronic address: carlo.catapano@ior.usi.ch.

Publikováno v: Cell metabolism [Cell Metab] 2019 Aug 06; Vol. 30 (2), pp. 303-318.e6. Date of Electronic Publication: 2019 May 23.